《新股消息》康方生物-B(09926.HK)超購638倍成「凍資王」 一手中籤率12%
康方生物-B(09926.HK)公布招股結果,發售價定於16.18元,為上限定價(招股價介乎14.88-16.18元)。公開發售錄超購638.2倍,凍結資金逾1,666億元,成為今年新股「凍資王」,在重新分配後,公開發售股數增至佔整體50%,申請一手1,000股中籤率僅12%。該股將於明日(24日)掛牌,聯席保薦人為摩根士丹利及摩根大通。
國際配售部分亦獲非常大幅超額認購。基石投資者已合共認購7,867.2萬股,佔緊隨全球發售完成後公司已發行股本約10.31%。基石投資者共9名,當中Fidelity Investments及Lake Bleu Prime Healthcare Master Funds Limited認購份額較大,分別購入3,137.3萬股及2,172萬股。
公司預計,所得集資淨額為24.37億元,當中75%將用作產品研發及商業化;15%將用於在中國廣州及中山發展生產及研發設施;10%將用於一般公司及營運資金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.